Approximately 100,000 people in the U.S. will be diagnosed with melanoma this year, according to the American Cancer Society.

The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.

A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ...